Crispr Therapeutics AG (NASDAQ:CRSP) Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the completion of the transaction, the director now owns 7,500 shares of the company’s stock, valued at $465,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of NASDAQ:CRSP traded up $0.97 during trading on Monday, hitting $66.33. 920,983 shares of the stock were exchanged, compared to its average volume of 713,132. The company has a fifty day moving average price of $60.48 and a two-hundred day moving average price of $48.87. The company has a market cap of $3.61 billion, a PE ratio of -19.28 and a beta of 3.30. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. Crispr Therapeutics AG has a 12-month low of $22.22 and a 12-month high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. The firm had revenue of $211.93 million during the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts anticipate that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
Several research firms have recently commented on CRSP. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. ValuEngine upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 1st. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, September 30th. Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Finally, Goldman Sachs Group lifted their target price on Crispr Therapeutics from $52.00 to $75.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 19th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have assigned a buy rating to the stock. Crispr Therapeutics currently has an average rating of “Buy” and an average price target of $69.54.
Several institutional investors have recently modified their holdings of CRSP. Xact Kapitalforvaltning AB acquired a new position in shares of Crispr Therapeutics during the 2nd quarter worth approximately $207,000. Commonwealth Equity Services LLC raised its holdings in Crispr Therapeutics by 5.9% in the 2nd quarter. Commonwealth Equity Services LLC now owns 17,815 shares of the company’s stock valued at $839,000 after acquiring an additional 986 shares during the last quarter. Buckley Wealth Management LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $236,000. Carnegie Capital Asset Management LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $1,064,000. Finally, Moody Aldrich Partners LLC acquired a new position in Crispr Therapeutics in the 2nd quarter valued at $1,838,000. Hedge funds and other institutional investors own 49.82% of the company’s stock.
Crispr Therapeutics Company Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: What is a front-end load?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.